Posted On: 05/25/2016 8:01:54 PM
Post# of 72443
Re: Loose Lips #23026
Indeed CTIX has accomplished exactly what they wanted to do.
"Nearly all biotechs developing a psoriasis drug target the moderate-to-severe patient class, but not Cellceutix in its Phase 2 study. Ehrlich explained that the company's confidence in Prurisol led to the decision to evaluate the drug under some of the most difficult situations, and that meant a short-duration study evaluating only one particular lesion in patients being treated with an oral drug (Prurisol). "It doesn't get much more difficult than that," Ehrlich said. "But, by going with a short study, we saved money, challenged our drug, and will have plenty of data for a late-stage trial."
Ehrlich further explained that by taking this approach, Cellceutix is assessing Prurisol's potential for two "huge markets," mild-to-moderate psoriasis and moderate-to-severe psoriasis. "It's a little more savvy approach than one might think at first blush," and one Ehrlich thinks the market may be overlooking."
https://www.thelifesciencesreport.com/pub/na/...al+3-14-16
"Nearly all biotechs developing a psoriasis drug target the moderate-to-severe patient class, but not Cellceutix in its Phase 2 study. Ehrlich explained that the company's confidence in Prurisol led to the decision to evaluate the drug under some of the most difficult situations, and that meant a short-duration study evaluating only one particular lesion in patients being treated with an oral drug (Prurisol). "It doesn't get much more difficult than that," Ehrlich said. "But, by going with a short study, we saved money, challenged our drug, and will have plenty of data for a late-stage trial."
Ehrlich further explained that by taking this approach, Cellceutix is assessing Prurisol's potential for two "huge markets," mild-to-moderate psoriasis and moderate-to-severe psoriasis. "It's a little more savvy approach than one might think at first blush," and one Ehrlich thinks the market may be overlooking."
https://www.thelifesciencesreport.com/pub/na/...al+3-14-16
Quote:
I stand corrected. This is an even better outcome for P as it meet the aggressive and difficult endpoints, while also showing it is potentially even more effective in the more severe cases. Seems like a extreme success to me.
(4)
(0)
Scroll down for more posts ▼
